Dr. Jennifer Chan is clinical director of the Gastrointestinal Cancer Center and director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute in Boston.
April 13, 2025
Video
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.
Finding Credible Voices in the Lynch Syndrome Community
Understanding Your Stage 2 Lymphoma Diagnosis
FDA Approves Revuforj for R/R NPM1-Mutant AML
How Does FDA-Approved Blenrep Treat Multiple Myeloma?